# A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

> **NCT06831370** · PHASE4 · RECRUITING · sponsor: **Takeda** · enrollment: 124 (estimated)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin
- **DRUG:** Doxorubicin
- **DRUG:** Vinblastine
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT06831370
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-28
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06831370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06831370, "A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06831370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*